Skip to content Skip to footer
Subscribe Now
Reuters Events Pharma Europe 2024
EVENTS

Reuters Events: Pharma Europe 2024

Align Purpose Unleash Innovation Unlock Healthcare Pharma’s role within the healthcare system is weakening. Increased demand, economic strains, suffocating regulatory change and a widening access gap is impacting future pipelines and commercial innovations reaching patients. Siloed functions too often compete with each other instead of complement each other, failing to rally behind a common purpose.…
April 8, 2024

Read more

VIEWPOINTS_Kari Wong_2024
VIEWPOINTS

Exploring Beyond: Kari Wong Sheds Light on Metabolon’s Strategic Collaboration with SITraN

Shots:   Following the strategic collaboration with the Sheffield Institute for Translational Neuroscience (SITraN), Metabolon’s scientific strategic director Kari Wong, engages in an illuminating conversation with PharmaShots    The collaboration aims to enhance the understanding of ALS and motor neuron disease (MND) by integrating a comprehensive biomarker approach to provide better diagnostics and therapeutics for these challenging…
April 8, 2024

Read more

VIEWPOINTS_Ahsan Arozullah_2024
VIEWPOINTS

A New Hope in Bladder Cancer Combination Therapy: PharmaShots in Conversation with Ahsan Arozullah

Shots:  Transformative combination therapies add wonder to oncology therapeutics now and then. Dr. Ahsan Arozullah, in another engaging conversation with PharmaShots, talks about Padcev + Keytruda therapy for adult patients suffering from locally advanced or metastatic urothelial cancer (la/mUC)  Ahsan shares insights from the P-III (EV-302) trial based on which the FDA accepted Padcev +…
April 2, 2024

Read more

VIEWPOINTS_David Jackson_2024
VIEWPOINTS

SEA Management with Fasenra: David Jackson & Fasenra Team (AZ) Share Insights from the SHAMAL P-IV Study

Shots:  David Jackson and AstraZeneca’s Fasenra Team, in an engaging conversation with PharmaShots highlight the key findings from the SHAMAL P-IV study  SHAMAL is the first-ever prospective study that investigated the potential of targeted biologic treatment to enable a significant step down of inhaled corticosteroid (ICS) therapy in severe asthma patients  SHAMAL showcased that ICS…
March 20, 2024

Read more

VIEWPOINTS_Richard Stefanacci_2024
VIEWPOINTS

Neurogenerative Disorders Management: Richard Stefanacci of TauRx in an Enlightening Conversation with PharmaShots

Shots:  Richard Stefanacci, Chief Medical Officer at TauRx, sheds light on the anti-tau drug Hydronomethylthionine mesylate (HMTM), a potential oral treatment for patients with Alzheimer’s disease and mild cognitive impairment  While highlighting the positive results from the LUCIDITY P-III study, Richard speaks about bridging the gap in AD and MCI treatment by lowering the dependence…
March 18, 2024

Read more

Post Conference Highlights E-Brain OncoVision Connecting the Dots in Cancer Care
EVENTS

Post Conference Highlights: E-Brain OncoVision: Connecting the Dots in Cancer Care

Riveting, insightful, and highly engaging, the two-day event by Ingenious e-brain remained a topic of discussion in the biopharma and healthcare community. PharmaShots as the official media partner had the opportunity to witness the first-ever metaverse-based virtual conference with distinguished keynote speakers from reputed biopharma companies, sharing insights on the present and the future of…
March 12, 2024

Read more

VIEWPOINTS_Susan Pandya_2024
VIEWPOINTS

Servier at SNO 2023: Dr. Susan Pandya Sheds Light on IDH-Mutant Diffuse Glioma Management

Shots:  In a stimulating conversation with PharmaShots, Dr. Susan Pandya shares insights from their presentation at SNO 2023 to strengthen Servier’s Neuro-Oncology Profile  While highlighting the details of vorasidenib, Susan articulately explains the study design of the P-III Indigo trial evaluating vorasidenib in patients with IDH-mutant diffuse glioma  With a fast-track designation and breakthrough therapy…
March 7, 2024

Read more

VIEWPOINTS_Philip M. Brown1_G. Michael Lewitt2_2024
VIEWPOINTS

Treating Plaque Psoriasis with VTAMA: Dermavant ‘s Philip M. Brown & G. Michael Lewitt in Conversation with PharmaShots

Shots:  G. Michael Lewitt and Philip M.Brown enlightened PharmaShots’ audience on Dermavant Sciences’ VTAMA cream a first-in-its-class topical prescription medication approved for Plaque Psoriasis  Michael & Philip discussed VTAMA’s study design along with its MOA, ROA, and formulation while shedding light on P-IV data  Philip further goes ahead to share details on VTAMA’s ongoing study…
February 29, 2024

Read more

Load more